An Introduction to Headache Disorders
Headache disorders are among the most prevalent and incapacitating conditions worldwide, accounting for nearly three-quarters of all neurological-related disabilities. Primary headache disorders encompass migraine, tension headache, and cluster headache, while medication-overuse headache stands as the prevailing form of secondary headache. Over the past decade, significant advancements in headache management have emerged, revolutionizing the treatment landscape. Notably, novel therapeutic approaches have honed in on targeting the CGRP (calcitonin gene-related peptide) ligand or receptor, thereby reshaping the treatment paradigm for migraines and exhibiting efficacy in combatting cluster headache. Additionally, a fresh avenue of intervention comes in the form of ditans, gepants and monoclonal antibodies, with many forms of medications being delivered by different approaches such as skin patches and nasal sprays, thereby reducing patient burden. These breakthroughs hold great promise in alleviating the burden of headache disorders, fostering improved quality of life for affected individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.
Our supporting partners do not constitute an endorsement of the content on this page.
Headache Disorders Content
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies
Shining a light on the burden of migraine and exploring real-world evidence on anti-CGRP antibodies.
- Explain the impact of migraine on patient quality of life and the importance of prevention
- Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
Peter Goadsby, EAN 2023: Highlights in migraine
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a new potential biomarker of visual snow syndrome, and the second a presentation that he […]
Peter Goadsby, EAN 2023: Highlights in headache disorders
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of headache disorders. He highlights two important presentations using calcitonin gene-related peptide […]
Highlights from EAN 2023!
Oral migraine therapy: targeting calcitonin gene-related peptide (CGRP)
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
Vydura®▼ (rimegepant) Prescribing Information (PI) for Great Britain (GB) and Northern Ireland (NI)
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Stewart Tepper, AAN 2023: Significant reduction in migraine days with REN for migraine prevention: A double-blind randomized sham-controlled clinical trial
Migraine affects over 1 billion people worldwide causing significant disability and a socioeconomic burden. Preventive treatment is key to managing migraine, but it is often underutilized. Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes his presentation from the 75th AAN Annual Meeting, 2023. Remote electrical neuromodulation (REN), a non-pharmacological acute migraine treatment, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!